DNA初免-蛋白加强免疫策略增强E2蛋白与ISA 61 VG佐剂疫苗对牛病毒性腹泻病毒的免疫应答
本研究构建编码BVDV BJ1305株E2蛋白的质粒pcDNA3.1-E2,并用ISA 61 VG佐剂乳化重组E2蛋白,在小鼠中比较DNA疫苗、蛋白疫苗及DNA初免-蛋白加强(两次DNA初免后一次蛋白加强)三种方案。结果显示DNA初免-蛋白加强组E2特异性抗体滴度显著高于单独DNA或蛋白疫苗组,第三次免疫后血清TNF-α水平显著高于其他组,且该组小鼠在BVDV Oregon C24V攻毒后病毒血症显著减少、病理变化轻微、病毒抗原负荷低于对照组和单独免疫组。作者认为DNA初免-蛋白加强策略较单独免疫具有潜在优势,但其控制并根除牛群BVD的能力有待进一步研究。
要点
- DNA初免-蛋白加强组E2特异性抗体滴度显著高于单独DNA疫苗组和单独蛋白疫苗组。
- E2 DNA疫苗诱导的CD4+IFN-γ+ T细胞和CD8+IFN-γ+ T细胞占总CD3+ T细胞百分比高于其他方案。
- DNA初免-蛋白加强组第三次免疫后血清TNF-α水平显著高于其他组,攻毒后病毒血症显著减少、病理变化轻微、病毒抗原负荷较低。
核心结论
- DNA初免-蛋白加强免疫策略较单独免疫在预防BVDV方面具有潜在优势。
- 该疫苗策略控制并根除牛群BVD的能力有待进一步研究。
研究设计与样本
- 研究构建编码BVDV BJ1305株E2蛋白的质粒pcDNA3.1-E2,并制备纯化重组E2蛋白,以ISA 61 VG佐剂乳化后使用。
- 小鼠分别接受三次pcDNA3.1-E2免疫、三次重组E2蛋白免疫,或两次pcDNA3.1-E2初免后一次E2蛋白加强。
- 第三次免疫后用BVDV Oregon C24V株攻毒,评估疫苗保护效果。
主要发现
- 所有免疫小鼠均产生体液和细胞免疫应答。
- DNA初免-蛋白加强组E2特异性抗体滴度显著高于单独DNA疫苗组和单独蛋白疫苗组。
- E2 DNA疫苗诱导的CD4+IFN-γ+ T细胞和CD8+IFN-γ+ T细胞占总CD3+ T细胞百分比高于其他方案。
- 免疫小鼠主要抗体亚类为IgG1。
- DNA初免-蛋白加强组第三次免疫后血清TNF-α水平显著高于其他组;攻毒后病毒血症显著减少、病理变化轻微、病毒抗原负荷低于对照组和单独免疫组。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 该疫苗策略控制并根除牛群BVD的能力有待进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The aim of this study was to develop and test an optimal vaccination strategy against bovine viral diarrhea virus (BVDV) based on the E2 glycoprotein of the BJ1305 strain. To achieve higher E2-specific antibody titers and to broaden the cellular immune response, a plasmid encoding the E2 protein (pcDNA3.1-E2) was constructed and a purified recombinant E2 protein was generated. The E2 protein was emulsified in the adjuvant ISA 61 VG prior to administration. We immunized mice three times with pcDNA3.1-E2 or the recombinant E2 protein or primed twice with pcDNA3.1-E2 and boosted once with the E2 protein. To evaluate the protection against BVDV conferred by the vaccines, the mice were challenged with BVDV strain Oregon C24V after the third immunization. Although all immunized mice developed humoral and cellular immune responses, the E2-specific antibody titers in the DNA prime-protein boost group were significantly higher than those elicited by either the DNA or the protein vaccine. In addition, vaccination with the E2 DNA vaccine induced higher percentages of CD4+IFN-γ+ T cells and CD8+IFN-γ+ T cells among total CD3+ T cells than the other regimens. The predominant antibody subclass in the vaccinated mice was IgG1. Serum tumor necrosis factor alpha (TNF-α) levels in the DNA prime-protein boost group were significantly higher after the third immunization than in the other groups. Moreover, the mice treated with the DNA prime-protein boost vaccination regimen acquired protection against BVDV challenge, as shown by a significant reduction of viremia, only minor pathological changes, and a lower viral antigen burden than in the control and solo vaccinated mice. These results demonstrate the potential advantage of a DNA prime-protein boost vaccination approach over a solo vaccination for the prevention of BVDV. The ability of this vaccine strategy to control and eradicate BVD in herds warrants further investigation.
引用
- Cai D, Song Q, Duan C, et al. Enhanced immune responses to E2 protein and DNA formulated with ISA 61 VG administered as a DNA prime-protein boost regimen against bovine viral diarrhea virus. Vaccine. 2018. PMID: 30077483. doi:10.1016/j.vaccine.2018.07.054
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。